Your browser doesn't support javascript.
loading
Immunoregulatory functions of VISTA.
Nowak, Elizabeth C; Lines, J Louise; Varn, Frederick S; Deng, Jie; Sarde, Aurelien; Mabaera, Rodwell; Kuta, Anna; Le Mercier, Isabelle; Cheng, Chao; Noelle, Randolph J.
Afiliação
  • Nowak EC; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Lines JL; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Varn FS; Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Deng J; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Sarde A; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Mabaera R; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Kuta A; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Le Mercier I; ImmuNext, Inc., Lebanon, NH, USA.
  • Cheng C; Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Noelle RJ; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Immunol Rev ; 276(1): 66-79, 2017 03.
Article em En | MEDLINE | ID: mdl-28258694
Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Ig-containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos B7 / Imunoterapia / Anticorpos Monoclonais / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos B7 / Imunoterapia / Anticorpos Monoclonais / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article